Bryan, Garnier & Co. announces successful admission of ONI BioPharma Inc.’s common stock to listing and trading on NYSE Alternext Paris

Bryan, Garnier & Co. announces successful admission of ONI BioPharma Inc.’s common stock to listing and trading on NYSE Alternext Paris

News published on December Monday 15, 2008
Share on

Paris, December 15th 2008 - Bryan, Garnier & Co, the independent pan-European investment bank focused on growth companies, today announced the admission of ONI BioPharma Inc.’s common stock to listing and trading on NYSE Alternext Paris (NYSE Alternext Paris - ALONI – US6840231046). The company was previously listed on the American Stock Exchange (Alternext US).

This new listing will make ONI BioPharma the first US-based company to have its shares listed on Alternext Paris, beginning December 15, 2008.

Bryan, Garnier & Co. acted as sole listing sponsor and exclusive advisor to the company.

The transaction enables ONI BioPharma to get access to European stock markets and increase its investor coverage. It also demonstrates ONI’s confidence in the success of the launching of its first probiotic product (EvoraPlustm) and its willingness to be seen as a major and long-term player through the future marketing of its other products in the United States and internationally.

Established in 1996, ONI BioPharma is an early-stage biotechnology company aimed at adding value to novel technologies and products sourced from innovative research from internal discovery, at the University of Florida, at other academic centers, and from in-licensing from other biotechnology companies. ONI’s strategy is first to in-license or internally discover products and technologies, second to develop products up to and through human proof-of-concept studies (Phase II clinical trials of the U.S. Food and Drug Administration’s regulatory process), and third to partner with major pharmaceutical, biotechnology, or healthcare product firms for advanced clinical development and commercialization.

Virginie Lazès, Managing Partner at Bryan, Garnier & Co commented: “ONI BioPharma exemplifies the type of growth business we support at Bryan, Garnier & Co. This successful transaction demonstrates the ability of our experienced investment bankers to provide industry-specific advice and deliver solutions to our clients despite challenging capital markets. This operation confirms our position as a leading European investment bank in Healthcare.”

According to Christian Finan, Equity Capital Market Director at Bryan, Garnier & Co. “Providing ONI BioPharma with a European listing, will enable the company to enhance liquidity in its share price, and increase visibility for financing the future development of the company.”

Following eight other capital market operations since the beginning of 2008, this transaction confirms the leadership of Bryan, Garnier & Co with regards to the financing and capital raising of European growth companies. Since 1998, Bryan, Garnier & Co has successfully led more than 50 fundraisings for growth companies, having raised several hundred million Euros over the past few years thanks to an experienced team of investment bankers and sector specialists, who share with the bank’s clients their insightful knowledge of new technologies and capital markets.

Stanley B. Stein, Chief Executive Officer of ONI Biopharma, added: “We are delighted with the success of the listing on NYSE Alternext Paris. Bryan, Garnier & Co.’s capital markets experience and strong understanding of biotechnology business was primordial. It enabled us to carry out this novel transaction for a US growth company, in an extremely complicated financial environment. Overall, Bryan, Garnier & Co’s intervention combined a strong coordination of the transactional process with senior involvement.”      

About ONI BioPharma (

ONI BioPharma Inc. is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The Company has developed platform technologies for future products, which the Company expects to develop.  

About Bryan, Garnier & Co (

Bryan, Garnier & Co is an independent investment bank specialising in European TMT, Healthcare and Renewable Energies growth companies. Bryan, Garnier & Co is positioned in three activities: Equity Research & Brokerage, Asset Management and Corporate Finance.

With more than 80 professionals based in London, Paris and Geneva, Bryan, Garnier & Co. combines the range of services and the expertise of top-tier investment banks with the level of attention to clients of a boutique.

The Corporate Finance department of Bryan, Garnier & Co advises European privately or publicly-owned companies, entrepreneurs and financial investors in the following transactions:

  • Equity Capital Markets transactions
  • Private Placements
  • Mergers & Acquisitions
  • €10m private placement on behalf of Initiatives & Développements (ALIDA)
  • €11m private placement on behalf of Inspirational Stores
  • €11.5m private placement in the form of a convertible bond for GoAdv (GOAOC)
  • €8m in mezzanine financing for Orolia (ALORO)
  • Placement of the international tranche of a €28m convertible bond for Arkimedica (ARK)
  • €12m IPO on behalf of Ipsogen (ALIPS)
  • €11m fundraising on behalf of Job Partners
  • €7m follow-on offering on behalf of Medicrea (ALMED)
  • €53m follow-on offering on behalf of Risc Group (RSC)
  • €40m follow-on offering on behalf of Bioalliance (BIO)
  • €100m follow-on offering on behalf of Transgene (TSG)
  • Secondary placement of €45m on behalf of Parrot (PARRO)
  • Capital increase of  €66m on behalf of Sword Group (SWP)
  • Acquisition of the French, Italian and Spanish subsidiaries of Payzone by Proximania, Financial Advisor to the acquirer
  • Acquisition of VCS Timeless by Cegid, Financial Advisor to the Sellers
  • Acquisition of Civitas by Cegid, Financial Advisor to the Sellers
  • Acquisition of Infolog Solutions by Generix, Vendor Financial Advisor
  • Sale of Orsyp to its Management and Argos Soditic through a LBO, Vendor Financial Advisor
  • Sale of Cosmos-Bay Vectis to Solucom, Vendor Financial Advisor

Over the past 10 years, Bryan, Garnier & Co has become a specialist as a reference point vis-à-vis venture capital funds and feed capital funds for cross-border Private Placements in technology companies.


In addition, Bryan, Garnier & Co took an increasingly active role in European capital markets, acting as financial advisor on the following transactions:


The most recent transactions for which Bryan, Garnier & Co acted as advisor are the following:



Bryan, Garnier & Co is authorised and regulated by the Financial Services Authority (FSA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext Listing Sponsor, and is active on all European Capital Markets.

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities